carboxypeptidase X, M14 family member 2Genealiases: CPX2 · UNQ676
Q-omics provides the consensus-scored CPXM2 profile across patient tissues and cancer cell-line models. CPXM2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CPXM2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CPXM2 protein abundance shows 19,656 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, THCA, and PDAC as cancer lineages where CPXM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPXM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPXM2 survival associations across molecular data types. CPXM2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPXM2 RNA expression–survival associations across cancer types. High CPXM2 expression shows unfavorable associations in KIRP and BLCA, but favorable associations in LUAD, HNSC, UVM and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CPXM2 RNA expression.
This table summarizes CPXM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CPXM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPXM2 shows lower tumor expression in THCA, BLCA, COAD, KIRP, UCEC and BRCA. The THCA box plot shows higher CPXM2 RNA expression in normal versus tumor tissue (log2 FC = −1.892, t-test p < 0.001).
This table shows molecular features associated with CPXM2 in patient tissues and cancer cell lines. In patient samples, CPXM2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CPXM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
